The Event. The fiscal Q3 10-Q hit this morning. It puts hard numbers on the August offering I wrote up last week, and it puts a hard number on something I’ve been asking for since the original deep dive: the European commercial ramp.
The Reaction. The stock closed $0.70, down 21.3% from the $0.89 print on August 13 and 50% below the $1.40 approval-day close on July 24.
The Reality. The raise did not cure the going concern. The European launch is not ramping — it’s going backwards. Those two facts, together, are why this tape looks the way it does.
The offering, priced and sized. 55,555,556 shares plus accompanying warrants for 55,555,556 shares at a combined $0.99, warrant strike $1.10, five-year term, immediately exercisable. Underwriters exercised their option — but only on the warrants, taking 8,333,333 additional warrants and zero additional shares. Net proceeds: $51.1 million. Closed August 14. The implication: the underwriters passing on the extra shares while taking the extra warrants is the cheapest possible read on how the book felt about the equity. They wanted the optionality, not the stock.
The share count. 243,447,554 shares outstanding as of August 14, up from 187,096,998 at June 30. That’s a 30% increase in the denominator in six weeks, and it excludes 40.4M warrants outstanding at June 30, the 55.6M new August warrants, the 8.3M option warrants, 6.2M options, and $85.4M of ATM capacity parked behind a terminated prospectus supplement.
Going concern survived the $55M. This is the line that matters most. From the filing: cash and equivalents of $11.2 million at June 30 together with the $51.1M of net proceeds “will only be sufficient to fund our operations into the second quarter of calendar year 2027.” Substantial doubt about the ability to continue as a going concern is reaffirmed in the Liquidity note, the MD&A, and the risk factors. Why it matters: I wrote on August 13 that the $55M “plausibly funds the U.S. launch through the fiscal Q2 FY27 report in roughly February 2027.” Management’s own estimate lands in exactly that window — and they are telling you in a registered document that it isn’t twelve months of runway. A company that just got a first-in-class FDA approval and raised 5x its cash balance is still, by its own accounting, financing quarter to quarter.
Insiders bought the deal. GMS took 2,525,252 shares plus warrants at $0.99. CEO Bob Jahr took 151,515; CFO Lawrence Kenyon took 101,010. The tea leaf: the anchor showed up, which answers the question I flagged last week about whether GMS would let the public market set the clearing price alone. But note the size — roughly $2.5M from GMS against the $5.0M registered direct they wrote in May at $0.5855. That’s participation, not a defense of the cap table. The C-suite checks are small enough (~$150K and ~$100K) to read as alignment signaling rather than conviction sizing.
The Atlas clock and the Avondale exit. The March 2025 Avondale note is fully extinguished — Avondale converted $16.8M of principal and interest into 39,404,455 shares over the nine months, and the note is gone. What replaces it is the Atlas March 2026 Note: $20.3M of principal, accrued interest and exit fees at a 9.5% floor rate, maturing June 16, 2027, with the $3.0M per calendar quarter redemption right activating September 16, 2026 — every dollar carrying a 7.5% exit fee.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.